

**NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS OF GENETETHER THERAPEUTICS  
INC. TO BE HELD ON APRIL 11, 2023**

**NOTICE IS HEREBY GIVEN** that an Annual General Meeting (the “**Meeting**”) of the holders (the “**Shareholders**”) of voting Common Shares (the “**Common Shares**”) of GeneTether Therapeutics Inc. (the “**Corporation**”) will be held on April 11, 2023, at 9:00 a.m. (Eastern Time) at 376 Victoria Ave Suite 200, Westmount, Quebec H3Z 1C3 and virtually via live webcast at <https://us06web.zoom.us/j/88572210942> for the following purposes:

1. to receive the audited financial statements of the Corporation for the year ended December 31, 2021, together with the report of the auditors thereon;
2. to elect directors of the Corporation for the ensuing year;
3. to consider, and if thought appropriate, to pass an ordinary resolution to appoint Horne LLP as auditors of the Corporation for the ensuing and to authorize the directors to fix the auditors’ remuneration; and
4. to transact such other business as may properly be brought before the Meeting or any adjournment or adjournments thereof.

Shareholders are referred to the accompanying Management Information Circular (the “**Circular**”) for more detailed information with respect to the matters to be considered at the Meeting.

**The Corporation is offering a virtual option for Shareholders to listen to the Meeting via virtual webcast at: <https://us06web.zoom.us/j/88572210942>. Via the virtual webcast, guests will be able to listen to the Meeting but will not be able to vote. If you intend to listen to the Meeting via the virtual webcast, you must vote on the matters prior to the Meeting by proxy, appointing the person designated in the proxy form or voting instruction form. You will find important information and detailed instructions about how to participate in the Meeting in the Circular.**

**Due to the ongoing concerns related to the spread of the coronavirus (COVID-19) and in order to protect the health and safety of shareholders, employees and other stakeholders and the community, shareholders are strongly encouraged to listen to the Meeting via virtual webcast instead of attending the meeting in person, and to vote on the matters before the Meeting by proxy, appointing the person designated by management in the proxy form or voting instruction form.**

The Corporation reserves the right to take any additional precautionary measures deemed to be appropriate, necessary or advisable in relation to the Meeting in response to further developments in the COVID-19 pandemic and in order to ensure compliance with federal, provincial and local laws and orders, including without limitation: (i) holding the Meeting virtually or by providing a webcast of the Meeting; (ii) hosting the Meeting solely by means of remote communication; (iii) changing the Meeting date and/or changing the means of holding the Meeting; (iv) denying access to persons who exhibit cold or flu-like symptoms, or who have, or have been in close contact with someone who has, travelled outside of Canada within the 14 days immediately prior to the Meeting; and (v) such other measures as may be recommended by public health authorities in connection with gatherings of persons such as the Meeting. Should any such changes to the Meeting format occur, the Corporation will announce any and all of these changes by way of news release, which will be filed under the Corporation’s profile on the System for Electronic Document Analysis and Retrieval (“**SEDAR**”) at [www.sedar.com](http://www.sedar.com). We strongly recommend that you check the Corporation’s website prior to the Meeting for the most current information. In the event of any changes to the Meeting format due to the COVID-19 pandemic, the Corporation will not prepare or mail amended materials in respect of the Meeting.

**Record Date**

The Board of Directors have fixed March 7, 2023 as the Record Date for the Meeting. Holders of Common Shares of record at the close of business on March 7, 2023 are entitled to receive Notice of the Meeting and to vote thereat or at any adjournment(s) thereof.

**Delivery of Proxies**

In order to be represented by proxy at the Meeting, you must complete, date, and sign the enclosed Instrument of Proxy and deliver it to our transfer agent, Odyssey Trust Company. The Instrument of Proxy will not be valid and not be acted upon or voted unless it is completed as outlined in the Instrument of Proxy and the individual has deposited it with Odyssey Trust Company by either (i) email to [proxy@odysseytrust.com](mailto:proxy@odysseytrust.com), (ii) by facsimile to 1-800-517-4553, (iii) by mail to Odyssey Trust Company Trader's Bank Building 702, 67 Yonge Street, Toronto, ON M5E 1J8 or (iv) by visiting their website at <https://login.odysseytrust.com/pxlogin>, no later than 9:00 a.m. Eastern Time two business days preceding the date of the Meeting or any adjournment or postponement thereof.

If you are a non-registered holder of shares and have received these materials from your broker or another intermediary, please complete and return the voting instruction form or other authorization form provided to you by your broker or intermediary in accordance with the instructions provided. Failure to do so may result in your Common Shares not being eligible to be voted at the Meeting.

The form of proxy confers discretionary authority with respect to: (i) amendments or variations to the matters of business to be considered at the Meeting; and (ii) other matters that may properly come before the Meeting. As of the date hereof, management of the Corporation knows of no amendments, variations or other matters to come before the Meeting other than the matters set forth in this Notice of Annual General Meeting. Shareholders who are planning on returning the accompanying form of proxy are encouraged to review the Information Circular carefully before submitting the proxy form.

**BY ORDER OF THE BOARD OF DIRECTORS**

*(signed) "Roland Boivin"*

Roland Boivin  
Chief Executive Officer and Director

March 10, 2023